ATE254451T1 - Mittel und verfahren zur behandlung t-zellen vermittelter krankheiten - Google Patents

Mittel und verfahren zur behandlung t-zellen vermittelter krankheiten

Info

Publication number
ATE254451T1
ATE254451T1 AT96924371T AT96924371T ATE254451T1 AT E254451 T1 ATE254451 T1 AT E254451T1 AT 96924371 T AT96924371 T AT 96924371T AT 96924371 T AT96924371 T AT 96924371T AT E254451 T1 ATE254451 T1 AT E254451T1
Authority
AT
Austria
Prior art keywords
cell
mediated diseases
treating
condition
cell mediated
Prior art date
Application number
AT96924371T
Other languages
English (en)
Inventor
Irun R Cohen
Dana Elias
Meir Shinitzky
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE254451T1 publication Critical patent/ATE254451T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
AT96924371T 1995-07-05 1996-07-02 Mittel und verfahren zur behandlung t-zellen vermittelter krankheiten ATE254451T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases
PCT/US1996/011373 WO1997002016A1 (en) 1995-07-05 1996-07-02 Preparations and methods for the treatment of t cell mediated diseases

Publications (1)

Publication Number Publication Date
ATE254451T1 true ATE254451T1 (de) 2003-12-15

Family

ID=11067727

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96924371T ATE254451T1 (de) 1995-07-05 1996-07-02 Mittel und verfahren zur behandlung t-zellen vermittelter krankheiten

Country Status (22)

Country Link
EP (1) EP0837672B9 (de)
JP (2) JP4357595B2 (de)
KR (1) KR100435040B1 (de)
CN (1) CN1102382C (de)
AT (1) ATE254451T1 (de)
AU (1) AU714970B2 (de)
CA (1) CA2226013C (de)
CZ (1) CZ298A3 (de)
DE (1) DE69630787T2 (de)
DK (1) DK0837672T3 (de)
ES (1) ES2211963T3 (de)
HR (1) HRP960315A2 (de)
HU (1) HU223081B1 (de)
IL (2) IL114458A0 (de)
MX (1) MX9800190A (de)
NO (1) NO320363B1 (de)
PT (1) PT837672E (de)
SI (1) SI0837672T1 (de)
UY (1) UY24275A1 (de)
WO (1) WO1997002016A1 (de)
YU (1) YU40796A (de)
ZA (1) ZA965666B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en) 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
ES2433915T3 (es) 2002-05-21 2013-12-13 Irun R. Cohen Vacunas de ADN que codifican proteínas de choque térmico
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (en) * 2003-05-12 2004-11-18 Peptor Ltd. Compositions and methods for modulation of specific epitopes of hsp60
US20090202618A1 (en) * 2003-11-24 2009-08-13 Yeda Research & Development Co. Ltd Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
EP1835933A4 (de) 2005-01-04 2015-01-07 Yeda Res & Dev Hsp60, hsp60-peptide und t-zellen-impfstoffe zur immunmodulation
AU2006293420B2 (en) 2005-09-22 2011-06-30 Irun R. Cohen Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
KR19990028738A (ko) 1999-04-15
HUP9802834A3 (en) 2001-08-28
AU6484496A (en) 1997-02-05
ZA965666B (en) 1997-01-27
PT837672E (pt) 2004-03-31
NO320363B1 (no) 2005-11-28
HUP9802834A2 (hu) 1999-03-29
JP2009242412A (ja) 2009-10-22
ES2211963T3 (es) 2004-07-16
HRP960315A2 (en) 1998-02-28
SI0837672T1 (en) 2004-04-30
CZ298A3 (cs) 1998-06-17
EP0837672B1 (de) 2003-11-19
CN1102382C (zh) 2003-03-05
NO980013D0 (no) 1998-01-02
EP0837672A1 (de) 1998-04-29
CA2226013A1 (en) 1997-01-23
KR100435040B1 (ko) 2004-08-18
JPH11508899A (ja) 1999-08-03
DE69630787T2 (de) 2004-10-07
DE69630787D1 (de) 2003-12-24
NO980013L (no) 1998-02-19
EP0837672B9 (de) 2005-06-15
YU40796A (sh) 1998-11-05
IL122755A (en) 2004-07-25
DK0837672T3 (da) 2004-03-22
HU223081B1 (hu) 2004-03-29
MX9800190A (es) 1998-04-30
CN1193907A (zh) 1998-09-23
IL114458A0 (en) 1995-11-27
IL122755A0 (en) 1998-08-16
WO1997002016A1 (en) 1997-01-23
UY24275A1 (es) 2000-12-29
AU714970B2 (en) 2000-01-13
JP4357595B2 (ja) 2009-11-04
EP0837672A4 (de) 1999-01-27
CA2226013C (en) 2012-09-18

Similar Documents

Publication Publication Date Title
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
DE69636514D1 (de) Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
MXPA05012784A (es) Lipidos oxidados y usos de los mismos en el tratamiento de enfermedades y desordenes inflamatorios.
ATE181422T1 (de) Verfahren zur diagnose von praeklampsie
ATE254451T1 (de) Mittel und verfahren zur behandlung t-zellen vermittelter krankheiten
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
Kudielka et al. Biological bases of the stress response
PT952772E (pt) Processos de utilizacao de fagocitos mononuclears para promover a regeneracao axonal
DE60140960D1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
Huang et al. Clinical manual of dermatology
ATE302008T1 (de) Behandlung von entzündlichen erkrankungen
DE69319341D1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
Ito et al. CCR5 is a novel target for the treatment of experimental alopecia areata
FI963170A0 (fi) Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i
DE60319719D1 (de) Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie
Lempel The effect of subliminal stimulation of symbiotic fantasies on the treatment of polysubstance abusers.
UA28518A (uk) Спосіб визначення алергену у хворих на лікарську хворобу
Binner The relationship between denial and empathy among adult male sex offenders.
UA34283A (uk) Спосіб діагностики порушень імунологічного статусу у людини та тварин
FR2807757B1 (fr) Nouvelle proteine ulip/crmp humaine et son utilisation dans le diagnostic et la therapie des cancers et des syndromes neurologiques et paraneoplastiques
UA31310A (uk) Спосіб лікування хворих на розсіяний склероз
UA6640A (uk) Спосіб прогнозування загострення супутнього захворювання при активізації основної патології

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0837672

Country of ref document: EP